title: Current role and future perspectives of radioiodinated MIBG in the evaluation of dementia with Lewy bodies.
abstract: Dementia with Lewy bodies (DLB) is the second most common cause of degenerative dementia after Alzheimer's disease (AD). To improve the diagnosis of DLB, the latest diagnostic criteria incorporate findings from neuroimaging studies including sympathetic innervation imaging with iodine-123-metaiodobenzylguanidine (MIBG). According to these criteria a decreased MIBG myocardial uptake is an important finding supporting a clinical diagnosis of DLB. In this review the state of art and future perspectives of sympathetic innervation imaging by using MIBG in the diagnosis of DLB are discussed.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Treglia
authors.forename: Luca
authors.initials: L
authors.lastname: Ceriani
authors.affiliation: Department of Nuclear Medicine and PET/CT Center, Ente Ospedaliero Cantonale, via Ospedale, 12; zip code: 6500; Bellinzona, Switzerland. giorgiomednuc@libero.it.
authors.forename: Luca
authors.initials: L
authors.lastname: Giovanella
mesh_terms: D019797:3-Iodobenzylguanidine; D001692:Biological Transport; D003704:Dementia / Q000175:diagnosis / Q000000981:diagnostic imaging*; D003937:Diagnosis, Differential; D004298:Dopamine / Q000737:chemistry; D006801:Humans; D007457:Iodine Radioisotopes; D020961:Lewy Body Disease / Q000175:diagnosis / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; D004298:Dopamine